A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 3, 2014, Pages 271-282

  Hiligsmann, Mickaël ^a   Cooper, Cyrus ^b,c   Guillemin, Francis ^d,e   Hochberg, Marc C ^f,g   Tugwell, Peter ^h   Arden, Nigel ^c   Berenbaum, Francis ^i,j   Boers, Maarten ^k   Boonen, Annelies ^a,l   Branco, Jaime C ^m,n,o   Maria Luisa, Brandi ^p   Bruyère, Olivier ^q   Gasparik, Andrea ^r   Kanis, John A ^s   Kvien, Tore K ^t   Martel Pelletier, Johanne ^u   Pelletier, Jean Pierre ^u   Pinedo Villanueva, Rafael ^u   Pinto, Daniel ^v   Reiter Niesert, Susanne ^w   Rizzoli, René ^x   Rovati, Lucio C ^y   Severens, Johan L ^z   Silverman, Stuart ^aa   Reginster, Jean Yves ^q   more..

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITÉ DE LORRAINE   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m CEDOC ^*  (Puerto Rico)

ⁿ NOVA MEDICAL SCHOOL   (Portugal)

^o HOSPITAL EGAS MONIZ   (Portugal)

^p UNIVERSITY OF FLORENCE   (Italy)

^q UNIVERSITY OF LIÈGE   (Belgium)

^r UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^s UNIVERSITY OF SHEFFIELD   (United Kingdom)

^t DIAKONHJEMMET HOSPITAL   (Norway)

^u CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^v NORTHWESTERN UNIVERSITY   (United States)

^w Federal Institute for Drugs and Medical Devices (BfArM)   (Germany)

^x GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^y Rotta Research Laboratorium   (Italy)

^z ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^aa UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Comparative effectiveness; Cost effectiveness analysis; Cost utility analysis; Economics; Hand; Hip; Knee; Methods; Osteoarthritis; Outcome assessment; Reference case; Rheumatic disease

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL EFFECTIVENESS; CONSENSUS; CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EUROPEAN SOCIETY FOR CLINICAL AND ECONOMIC ASPECTS OF OSTEOPOROSIS AND OSTEOARTHRITIS; FUNCTIONAL STATUS; HAND OSTEOARTHRITIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; NON PROFIT ORGANIZATION; PAIN INTENSITY; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SELF REPORT; STANDARD; VALIDATION STUDY; VISUAL ANALOG SCALE; CONSENSUS DEVELOPMENT; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; ECONOMICS; EUROPE; HAND; MEDICAL SOCIETY; OSTEOARTHRITIS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; OUTCOME ASSESSMENT;

COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; EUROPE; HAND; HUMANS; OSTEOARTHRITIS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; OUTCOME ASSESSMENT (HEALTH CARE); SOCIETIES, MEDICAL;

EID: 84919675983     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.06.005     Document Type: Review

References (121)

1. Ethgen O., Bruyere O., Richy F., Dardennes C., Reginster J.Y. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am 2004, 86-A:963-974.
2. Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009, 15(Suppl 8):S230-S235.
3. Tarride J.E., Haq M., O'Reilly D.J., Bowen J.M., Xie F., Dolovich L., et al. The excess burden of osteoarthritis in the province of Ontario, Canada. Arthritis Rheum 2012, 64:1153-1161.
4. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
5. Hiligsmann M., Reginster J.Y. The economic weight of osteoarthritis in Europe. Medicographia 2013, 35:197-202.
6. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
7. Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681.
8. Zhang W., Doherty M., Leeb B.F., Alekseeva L., Arden N.K., Bijlsma J.W., et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66:377-388.
9. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
10. Osteoarthritis: the care and management of osteoarthritis in adults 2008, NICE: National Institute for Health and Clinical Excellence, [Accessed 15-11-2013]. http://guidance.nice.org.uk/CG59/NICEGuidance/pdf/English.
11. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
12. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012, 64:465-474.
13. Taylor R.S., Drummond M.F., Salkeld G., Sullivan S.D. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. Br Med J 2004, 329:972-975.
14. Pinto D., Robertson M.C., Hansen P., Abbott J.H. Cost-effectiveness of nonpharmacologic, nonsurgical interventions for hip and/or knee osteoarthritis: systematic review. Value Health 2012, 15:1-12.
15. Hiligsmann M., Cooper C., Arden N., Boers M., Branco J.C., Luisa B.M., et al. Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013, 43:303-313.
16. Frederix G.W., Severens J.L., Hovels A.M., Raaijmakers J.A., Schellens J.H. The cloudy crystal ball of cost-effectiveness studies. Value Health 2013, 16:1100-1102.
17. Siegel J.E., Torrance G.W., Russell L.B., Luce B.R., Weinstein M.C., Gold M.R. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997, 11:159-168.
18. Gabriel S.E., Tugwell P., Drummond M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Ann Rheum Dis 2002, 61:370-373.
19. Gabriel S., Drummond M., Maetzel A., Boers M., Coyle D., Welch V., et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003, 30:886-890.
20. Maetzel A., Tugwell P., Boers M., Guillemin F., Coyle D., Drummond M., et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003, 30:891-896.
21. Drummond M., Maetzel A., Gabriel S., March L. Towards a reference case for use in future economic evaluations of interventions in osteoarthritis. J Rheumatol Suppl 2003, 68:26-30.
22. Bansback N., Maetzel A., Drummond M., Anis A., Marra C., Conway P., et al. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. J Rheumatol 2007, 34:1178-1183.
23. Zethraeus N., Borgstrom F., Strom O., Kanis J.A., Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 2007, 18:9-23.
24. Ramsey S., Willke R., Briggs A., Brown R., Buxton M., Chawla A., et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005, 8:521-533.
25. Arden N., Nevitt M.C. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006, 20:3-25.
26. Berger M.L., Mamdani M., Atkins D., Johnson M.L. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health 2009, 12:1044-1052.
27. Cox E., Martin B.C., Van Staa T., Garbe E., Siebert U., Johnson M.L. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health 2009, 12:1053-1061.
28. Berger M.L., Dreyer N., Anderson F., Towse A., Sedrakyan A., Normand S.L. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health 2012, 15:217-230.
29. Lyles A. The reference case ten years later: has comparing cost-effectiveness analyses improved?. Clin Ther 2006, 28:1182-1183.
30. Drummond M.F., Sculpher M.J. Better analysis for better decisions: facing up to the challenges. Pharmacoeconomics 2006, 24:1039-1042.
31. Husereau D., Drummond M., Petrou S., Carswell C., Moher D., Greenberg D., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Br Med J 2013, 346:1.
32. Moher D., Hopewell S., Schulz K.F., Montori V., Gotzsche P.C., Devereaux P.J., et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Br Med J 2010, 10.1136/bmj.c869.
33. Larson E.L., Cortazal M. Publication guidelines need widespread adoption. J Clin Epidemiol 2012, 65:239-246.
34. Husereau D., Drummond M., Petrou S., Carswell C., Moher D., Greenberg D., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013, 16:231-250.
35. Guyatt G.H., Oxman A.D., Kunz R., Atkins D., Brozek J., Vist G., et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011, 64:395-400.
36. Huang X., Lin J., Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc 2006, 359-363.
37. Zwarenstein M., Treweek S., Gagnier J.J., Altman D.G., Tunis S., Haynes B., et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Br Med J 2008, 10.1136/bmj.a2390.
38. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007, 85:867-872.
39. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
40. Sculpher M.J., Claxton K., Drummond M., McCabe C. Whither trial-based economic evaluation for health care decision making?. Health Econ 2006, 15:677-687.
41. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics 2000, 17:443-444. Decision analytic modelling in the economic evaluation of health technologies.
42. Sculpher M., Fenwick E., Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 2000, 17:461-477.
43. Altman R., Alarcon G., Appelrouth D., Bloch D., Borenstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990, 33:1601-1610.
44. Altman R., Alarcon G., Appelrouth D., Bloch D., Borenstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34:505-514.
45. Cooper C., Arden N.K. Excess mortality in osteoarthritis. Br Med J 2011, 10.1136/bmj.d1407.
46. Losina E., Walensky R.P., Reichmann W.M., Holt H.L., Gerlovin H., Solomon D.H., et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011, 154:217-226.
47. Nuesch E., Dieppe P., Reichenbach S., Williams S., Iff S., Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. Br Med J 2011, 10.1136/bmj.d1165.
48. Culliford D.J., Maskell J., Kiran A., Judge A., Javaid M.K., Cooper C., et al. The lifetime risk of total hip and knee arthroplasty: results from the UK general practice research database. Osteoarthritis Cartilage 2012, 20:519-524.
49. Prieto-Alhambra D., Judge A., Javaid M.K., Cooper C., Diez-Perez A., Arden N.K. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of ae, gender and osteoarthritis affecting other joints. Ann Rheum Dis 2013, in press. 10.1136/annrheumdis-2013-203355.
50. Lane N.E., Brandt K., Hawker G., Peeva E., Schreyer E., Tsuji W., et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage 2011, 19:478-482.
51. de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003, 56:221-229.
52. Singh J.A., Nelson D.B., Fink H.A., Nichol K.L. Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: the veterans arthritis quality of life study. Semin Arthritis Rheum 2005, 34:755-765.
53. Tuominen U., Blom M., Hirvonen J., Seitsalo S., Lehto M., Paavolainen P., et al. The effect of co-morbidities on health-related quality of life in patients placed on the waiting list for total joint replacement. Health Qual Life Outcomes 2007, 5:16.
54. Massey T., Derry S., Moore R.A., McQuay H.J. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev 2010, 16(6):CD007402.
55. Roddy E., Doherty M. Changing life-styles and osteoarthritis: what is the evidence?. Best Pract Res Clin Rheumatol 2006, 20:81-97.
56. Messier S.P., Mihalko S.L., Legault C., Miller G.D., Nicklas B.J., DeVita P., et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. J Am Med Assoc 2013, 310:1263-1273.
57. Nelson A.E., Allen K.D., Golightly Y.M., Goode A.P., Jordan J.M. A systematic review of recommendations and guidelines for the management of osteoarthritis: the Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 2013, 13:10.
58. Brouwer R.W., van Raaij T.M., Bierma-Zeinstra S.M., Verhagen A.P., Jakma T.S., Verhaar J.A. Osteotomy for treating knee osteoarthritis. Cochrane Database Syst Rev 2007, CD004019.
59. Intema F., Van Roermund P.M., Marijnissen A.C., Cotofana S., Eckstein F., Castelein R.M., et al. Tissue structure modification in knee osteoarthritis by use of joint distraction: an open 1-year pilot study. Ann Rheum Dis 2011, 70:1441-1446.
60. Grotle M., Hagen K.B., Natvig B., Dahl F.A., Kvien T.K. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008, 9:132-139.
61. Uthman O.A., van der Windt D.A., Jordan J.L., Dziedzic K.S., Healey E.L., Peat G.M., et al. Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis. Br Med J 2013, 347:f5555.
62. Gossec L., Hawker G., Davis A.M., Maillefert J.F., Lohmander L.S., Altman R., et al. OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. J Rheumatol 2007, 34:1432-1435.
63. Gossec L., Paternotte S., Bingham C.O., Clegg D.O., Coste P., Conaghan P.G., et al. OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol 2011, 38:1765-1769.
64. Faulkner A., Kennedy L.G., Baxter K., Donovan J., Wilkinson M., Bevan G. Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model. Health Technol Assess 1998, 2:1-133.
65. Odum S.M., Troyer J.L., Kelly M.P., Dedini R.D., Bozic K.J. A cost-utility analysis comparing the cost-effectiveness of simultaneous and staged bilateral total knee arthroplasty. J Bone Joint Surg Am 2013, 95:1441-1449.
66. de Groot N.L., Spiegel B.M., van Haalen H.G., de Wit N.J., Siersema P.D., van Oijen M.G. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components. Value Health 2013, 16:769-777.
67. Weinstein M.C., O'Brien B., Hornberger J., Jackson J., Johannesson M., McCabe C., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003, 6:9-17.
68. Claxton K., Cohen J.T., Neumann P.J. When is evidence sufficient?. Health Affairs 2005, 24:93-101.
69. Harrison M.J., Bansback N.J., Marra C.A., Drummond M., Tugwell P.S., Boonen A. Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol 2011, 38:1770-1775.
70. Bellamy N., Kirwan J., Boers M., Brooks P., Strand V., Tugwell P., et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997, 24:799-802.
71. Boers M., Kirwan J.R., Wells G., Beaton D., Gossec L., D'Agostino M.A., et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014, 67(7):745-753.
72. Committee For Medicinal Products for Human use (CHMP) Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. CPMP/EWP/784/97 Rev. 1 2010.
73. Litcher-Kelly L., Martino S.A., Broderick J.E., Stone A.A. A systematic review of measures used to assess chronic musculoskeletal pain in clinical and randomized controlled clinical trials. J Pain 2007, 8:906-913.
74. Hawker G.A., Stewart L., French M.R., Cibere J., Jordan J.M., March L., et al. Understanding the pain experience in hip and knee osteoarthritis-an OARSI/OMERACT initiative. Osteoarthritis Cartilage 2008, 16:415-422.
75. Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage 2013, 21:1145-1153.
76. Chung K.C., Pillsbury M.S., Walters M.R., Hayward R.A. Reliability and validity testing of the Michigan Hand Outcomes Questionnaire. J Hand Surg Am 1998, 23:575-587.
77. Murray D.W., Fitzpatrick R., Rogers K., Pandit H., Beard D.J., Carr A.J., et al. The use of the Oxford hip and knee scores. J Bone Joint Surg Br 2007, 89:1010-1014.
78. Nilsdotter A.K., Lohmander L.S., Klassbo M., Roos E.M. Hip disability and osteoarthritis outcome score (HOOS)-validity and responsiveness in total hip replacement. BMC Musculoskelet Disord 2003, 4:10.
79. Roos E.M., Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS)-validation and comparison to the WOMAC in total knee replacement. Health Qual Life Outcomes 2003, 1:17.
80. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
81. Hawker G.A., Davis A.M., French M.R., Cibere J., Jordan J.M., March L., et al. Development and preliminary psychometric testing of a new OA pain measure-an OARSI/OMERACT initiative. Osteoarthritis Cartilage 2008, 16:409-414.
82. Guillemin F., Coste J., Pouchot J., Ghezail M., Bregeon C., Sany J. The AIMS2-SF: a short form of the Arthritis Impact Measurement Scales 2. French Quality of Life in Rheumatology Group. Arthritis Rheum 1997, 40:1267-1274.
83. Dreiser R.L., Maheu E., Guillou G.B., Caspard H., Grouin J.M. Validation of an algofunctional index for osteoarthritis of the hand. Rev Rhum Engl Ed 1995, 62(6 Suppl 1):43S-53S.
84. Lequesne M.G. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol 1997, 24:779-781.
85. van Groen M.M., ten Klooster P.M., Taal E., van de Laar M.A., Glas C.A. Application of the health assessment questionnaire disability index to various rheumatic diseases. Qual Life Res 2010, 19:1255-1263.
86. Busija L., Osborne R.H., Roberts C., Buchbinder R. Systematic review showed measures of individual burden of osteoarthritis poorly capture the patient experience. J Clin Epidemiol 2013, 66:826-837.
87. Arden N.K., Kiran A., Judge A., Biant L.C., Javaid M.K., Murray D.W., et al. What is a good patient reported outcome after total hip replacement?. Osteoarthritis Cartilage 2011, 19:155-162.
88. Fries J.F., Cella D., Rose M., Krishnan E., Bruce B. Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol 2009, 36:2061-2066.
89. Cella D., Yount S., Rothrock N., Gershon R., Cook K., Reeve B., et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007, 45(5 Suppl 1):S3-S11.
90. Towards a common language for functioning, disability and health-the international classification of functioning, disability and health 2002, World Health Organisation, WHO, [accessed 16.12.2013]. http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf.
91. Woodworth T., Furst D.E., Alten R., Bingham C., Yocum D., Sloan V., et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 2007, 34:1401-1414.
92. Boonen A., Maetzel A., Drummond M., Suarez-Almazor M., Harrison M., Welch V., et al. The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. J Rheumatol 2009, 36:2045-2049.
93. Joore M., Brunenberg D., Nelemans P., Wouters E., Kuijpers P., Honig A., et al. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies. Value Health 2010, 13:222-229.
94. Gaujoux-Viala C., Rat A.C., Guillemin F., Flipo R.M., Fardellone P., Bourgeois P., et al. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2012, 71:1478-1483.
95. Ethgen O., Tancredi A., Lejeune E., Kvasz A., Zegels B., Reginster J.Y. Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC Index. J Rheumatol 2003, 30:2452-2459.
96. Pinedo-Villanueva R.A., Turner D., Judge A., Raftery J.P., Arden N.K. Mapping the Oxford hip score onto the EQ-5D utility index. Qual Life Res 2013, 22:665-675.
97. Ades A.E., Lu G., Madan J.J. Which health-related quality-of-life outcome when planning randomized trials: disease-specific or generic, or both? A common factor model. Value Health 2013, 16:185-194.
98. Longworth L., Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health 2013, 16:202-210.
99. Mittendorf T., Merkesdal S., Huelsemann J.L., von der Schulenburg J.M., Zeidler H., Ruof J. Implementing standardized cost categories within economic evaluations in musculoskeletal diseases. Eur J Health Econ 2003, 4:43-49.
100. Birnbaum H. Friction-cost method as an alternative to the human-capital approach in calculating indirect costs. Pharmacoeconomics 2005, 23:103-104.
101. Knies S., Boonen A., Candel M.J., Evers S.M., Severens J.L. Compensation mechanisms for lost productivity: a comparison between four European countries. Value Health 2013, 16:740-744.
102. Mattke S., Balakrishnan A., Bergamo G., Newberry S.J. A review of methods to measure health-related productivity loss. Am J Manag Care 2007, 13:211-217.
103. Schultz A.B., Chen C.Y., Edington D.W. The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics 2009, 27:365-378.
104. Lundberg M., Grimby-Ekman A., Verbunt J., Simmonds M.J. Pain-related fear: a critical review of the related measures. Pain Res Treat 2011, 2011:494196.
105. Pollard B., Johnston M., Dieppe P. What do osteoarthritis health outcome instruments measure? Impairment, activity limitation, or participation restriction?. J Rheumatol 2006, 33:757-763.
106. Dworkin R.H., Peirce-Sandner S., Turk D.C., McDermott M.P., Gibofsky A., Simon L.S., et al. Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database. Osteoarthritis Cartilage 2011, 19:483-492.
107. Pollard B., Johnston M., Dieppe P. Exploring the relationships between International Classification of Functioning, Disability and Health (ICF) constructs of impairment, activity limitation and participation restriction in people with osteoarthritis prior to joint replacement. BMC Musculoskelet Disord 2011, 12:97.
108. Dougados M., Leclaire P., van der H.D., Bloch D.A., Bellamy N., Altman R.D. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000, 8:395-403.
109. Cooper C., Adachi J.D., Bardin T., Berenbaum F., Flamion B., Jonsson H., et al. How to define responders in osteoarthritis. Curr Med Res Opin 2013, 29:719-729.
110. Perrot S., Bertin P. "Feeling better" or "feeling well" in usual care of hip and knee osteoarthritis pain: determination of cutoff points for patient acceptable symptom state (PASS) and minimal clinically important improvement (MCII) at rest and on movement in a national multicenter cohort study of 2414 patients with painful osteoarthritis. Pain 2013, 154:248-256.
111. Escobar A., Gonzalez M., Quintana J.M., Vrotsou K., Bilbao A., Herrera-Espineira C., et al. Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values. Osteoarthritis Cartilage 2012, 20:87-92.
112. Sullivan P.W., Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006, 26:410-420.
113. Ko Y., Coons S.J. Self-reported chronic conditions and EQ-5D index scores in the US adult population. Curr Med Res Opin 2006, 22:2065-2071.
114. Manton K.G. Recent declines in chronic disability in the elderly U.S. population: risk factors and future dynamics. Annu Rev Public Health 2008, 29:91-113.
115. Brazier J. Valuing health States for use in cost-effectiveness analysis. Pharmacoeconomics 2008, 26:769-779.
116. Busse R., van Ginneken E., Schreyögg J., Garrido M.V. Benefit baskets and tariffs. Cross-border Health Care in the European Union. European Observatory on Health Systems and Policies 2011, 91-120. M. Wismar, W. Palm, J. Figueras, K. Ernst, E. van Ginneken (Eds.).
117. Dere W., Avouac B., Boers M., Buxton M., Christiansen C., Dawson A., et al. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 1998, 63:93-97.
118. Lotz M., Martel-Pelletier J., Christiansen C., Brandi M.L., Bruyere O., Chapurlat R., et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 2013, 72:1756-1763.
119. Kumm J., Tamm A., Lintrop M., Tamm A. The value of cartilage biomarkers in progressive knee osteoarthritis: cross-sectional and 6-year follow-up study in middle-aged subjects. Rheumatol Int 2013, 33:903-911.
120. Ornetti P., Brandt K., Hellio-Le Graverand M.P., Hochberg M., Hunter D.J., Kloppenburg M., et al. OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis. Osteoarthritis Cartilage 2009, 17:856-863.
121. Kirkham J.J., Boers M., Tugwell P., Clarke M., Williamson P.R. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials 2013, 14:324.